Evidence map›Paper›PMID 37069150›Full record

ArticleNature communications2023

DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age.

Jos Urbanus, Jason Cosgrove, Joost B Beltman, Yuval Elhanati, Rafael A Moral, Cecile Conrad, Jeroen W van Heijst, Emilie Tubeuf, Arno Velds, Lianne Kok and 10 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 5 countries.

Jos Urbanus *Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-3074-8477
Jason Cosgrove *Institut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, 75005, Paris, France.
Joost B BeltmanDivision of Drug Discovery & Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.ORCID 0000-0001-9215-3087
Yuval ElhanatiMemorial Sloan Kettering Cancer Center, New York, USA.
Rafael A MoralDepartment of Mathematics and Statistics, Maynooth University, Maynooth, Ireland.
Cecile ConradInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, 75005, Paris, France.
Jeroen W van HeijstDivision of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Emilie TubeufInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, 75005, Paris, France.
Arno VeldsDivision of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-4333-8872
Lianne KokDivision of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Candice MerleInstitut Curie, Laboratory of Genetics and Developmental Biology, PSL Research University, INSERM U934, CNRS UMR3215, Paris, France.
Jens P MagnussonDepartment of Bioengineering, Stanford University, Stanford, USA.ORCID 0000-0002-3928-8959
Léa GuyonnetCytometry Platform, Institut Curie, 75005, Paris, France.
Jonas FrisénDepartment of Cell and Molecular Biology, Karolinska Institute, Solna, Sweden.ORCID 0000-0001-5819-458X
Silvia FreInstitut Curie, Laboratory of Genetics and Developmental Biology, PSL Research University, INSERM U934, CNRS UMR3215, Paris, France.ORCID 0000-0002-7209-7636
Aleksandra M WalczakLaboratoire de Physique de l'École Normale Supérieure (PSL University), CNRS, Sorbonne Université, and Université de Paris, Paris, France.ORCID 0000-0002-2686-5702
Thierry MoraLaboratoire de Physique de l'École Normale Supérieure (PSL University), CNRS, Sorbonne Université, and Université de Paris, Paris, France.
Heinz JacobsDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-6227-9850
Ton N SchumacherDivision of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.ORCID 0000-0003-0517-8804
Leïla PeriéInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, 75005, Paris, France. leila.perie@curie.fr.ORCID 0000-0003-0798-4498
Centre National de la Recherche Scientifique · FRThe Netherlands Cancer Institute · NLInstitut Curie · FRKarolinska Institutet · SELeiden University · NLLeiden University Medical Center · NLMemorial Sloan Kettering Cancer Center · USNational University of Ireland, Maynooth · IEStanford University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Ageing is associated with changes in the cellular composition of the immune system. During ageing, hematopoietic stem and progenitor cells (HSPCs) that produce immune cells are thought to decline in their regenerative capacity. However, HSPC function has been mostly assessed using transplantation assays, and it remains unclear how HSPCs age in the native bone marrow niche. To address this issue, we present an in situ single cell lineage tracing technology to quantify the clonal composition and cell production of single cells in their native niche. Our results demonstrate that a pool of HSPCs with unequal output maintains myelopoiesis through overlapping waves of cell production throughout adult life. During ageing, the increased frequency of myeloid cells is explained by greater numbers of HSPCs contributing to myelopoiesis rather than the increased myeloid output of individual HSPCs. Strikingly, the myeloid output of HSPCs remains constant over time despite accumulating significant transcriptomic changes throughout adulthood. Together, these results show that, unlike emergency myelopoiesis post-transplantation, aged HSPCs in their native microenvironment do not functionally decline in their regenerative capacity.

Indexed as

Hematopoietic Stem CellsMyelopoiesisAdultAgedBone MarrowBone Marrow CellsHumansMyeloid Cells

Identifiers

PMID37069150
PMCPMC10110593
OpenAlexW4366086073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.